» Articles » PMID: 30097693

Neuroimaging of Central Diabetes Insipidus-when, How and Findings

Overview
Journal Neuroradiology
Specialties Neurology
Radiology
Date 2018 Aug 12
PMID 30097693
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Central or neurogenic diabetes insipidus (CDI) is due to deficient synthesis or secretion of antidiuretic hormone (ADH), also known as arginine vasopressin peptide (AVP). It is clinically characterised by polydipsia and polyuria (urine output > 30 mL/kg/day) of dilute urine (< 250 mOsm/L). It is the result of a defect in one of more sites involving the hypothalamic osmoreceptors, supraoptic or paraventricular nuclei of the hypothalamus, median eminence of the hypothalamus, infundibulum or the posterior pituitary gland. A focused MRI pituitary gland or sella protocol is essential. There are several neuroimaging correlates and causes of CDI, illustrated in this review. The most common causes are benign or malignant neoplasms of the hypothalamic-pituitary axis (25%), surgery (20%), head trauma (16%) or familial causes (10%). No cause is identified in up to 30% of cases. Knowledge of the anatomy and physiology of the hypothalamo-neurohypophyseal axis is crucial when evaluating a patient with CDI. Establishing the aetiology of CDI with MRI in combination with clinical and biochemical assessment facilitates appropriate targeted treatment. The aim of the pictorial review is to illustrate the wide variety of causes of CDI on neuroimaging, highlight the optimal MRI protocol and to revise the detailed neuroanatomy and neurophysiology required to interpret these studies.

Citing Articles

Deficiency of arginine vasopressin in children - diagnostic and therapeutic approaches to improve patients' quality of life based on a 25-year, single-centre retrospective analysis.

Roztoczynska D, Iwanska A, Wedrychowicz A, Janus D, Zygmunt-Gorska A, Wojcik M Pediatr Endocrinol Diabetes Metab. 2025; 30(4):198-210.

PMID: 39963057 PMC: 11809552. DOI: 10.5114/pedm.2024.146684.


Endocrine side effects of immune checkpoint inhibitors.

Cardona Z, Sosman J, Chandra S, Huang W Front Endocrinol (Lausanne). 2023; 14:1157805.

PMID: 37251665 PMC: 10210589. DOI: 10.3389/fendo.2023.1157805.


Idiopathic partial central diabetes insipidus.

Fabre L, Calice da Silva V Einstein (Sao Paulo). 2023; 21:eRC0124.

PMID: 36790249 PMC: 9897711. DOI: 10.31744/einstein_journal/2023RC0124.


Panhypopituitarism Mimicking Acute Coronary Syndrome.

Sugi Y, Mori K, Kobayashi T, Arai N, Okano M, Muramae N Intern Med. 2022; 62(4):559-564.

PMID: 35705269 PMC: 10017242. DOI: 10.2169/internalmedicine.0031-22.


Change in cephalocaudal tumor cavity diameter after transsphenoidal surgery is a predictor of diabetes insipidus in pituitary adenoma.

Lin K, Fan K, Mu S, Wang S Eur J Med Res. 2022; 27(1):72.

PMID: 35614499 PMC: 9131668. DOI: 10.1186/s40001-022-00700-4.


References
1.
Edate S, Albanese A . Management of electrolyte and fluid disorders after brain surgery for pituitary/suprasellar tumours. Horm Res Paediatr. 2015; 83(5):293-301. DOI: 10.1159/000370065. View

2.
Brooks B, El Gammal T, Allison J, Hoffman W . Frequency and variation of the posterior pituitary bright signal on MR images. AJNR Am J Neuroradiol. 1989; 10(5):943-8. PMC: 8335287. View

3.
CARPENTER K, Murtagh R, Lilienfeld H, Weber J, Murtagh F . Ipilimumab-induced hypophysitis: MR imaging findings. AJNR Am J Neuroradiol. 2009; 30(9):1751-3. PMC: 7051497. DOI: 10.3174/ajnr.A1623. View

4.
Di Iorgi N, Napoli F, Allegri A, Olivieri I, Bertelli E, Gallizia A . Diabetes insipidus--diagnosis and management. Horm Res Paediatr. 2012; 77(2):69-84. DOI: 10.1159/000336333. View

5.
Chiloiro S, Giampietro A, Bianchi A, De Marinis L . Clinical management of teratoma, a rare hypothalamic-pituitary neoplasia. Endocrine. 2015; 53(3):636-42. DOI: 10.1007/s12020-015-0814-4. View